Blog
Blog
The CI Capacity Squeeze, and Three Questions To Ask Before 2027 Planning
Every year the competitive field gets more crowded: more assets, more readouts, more congress abstracts, more competitor moves to track. Products are more complex too, from special distribution to patient and healthcare professional (HCP) education requirements. And every year, pharma competitive intelligence (CI) teams are asked to cover more of it. What’s changed is that resources aren’t keeping up.
Filter posts by:
Blog
How AI and Patient-Level Data Help Oncology Teams Define New Markets
Oncology markets are no longer defined only by tumor type or line of therapy. AI, patient-level data, and primary research now help teams define markets by biology, care pathways, and access barriers. That shift can shape development strategy, trial design, and...
Blog
Pharma’s Quiet Channel Shift: What Direct-to-Patient Models Mean for Commercial Teams
Direct-to-patient (DTP) channels have quietly moved from the margins of pharma to a central lever in high-demand categories. One-third of new Zepbound prescriptions in the U.S. are now being filled through LillyDirect, bypassing insurers, PBMs, and traditional pharmacy channels entirely. A...
Blog
Integrating Human and Artificial Intelligence: What I Told New to the Street About the Future of Commercialization
Scott Evangelista Chief Executive Officer When I sat down with Jane King on New to the Street, I had one message I wanted every viewer to walk away with. Trinity is the leader integrating human and artificial intelligence in commercialization. Life...
Blog
From Insights to Impact: How AI Is Transforming Pharmaceutical Competitive Intelligence
Pharmaceutical competitive intelligence (CI) has quietly become one of pharma’s most strained functions. The TGaS Competitive Intelligence Landscape Survey (October 2025) shows competitive complexity accelerating at a pace that traditional CI models cannot absorb.
Blog
Why Enterprise AI Feels Like a Disappointment for Life Sciences Teams
You have used tools like ChatGPT. They are fast, helpful, almost fun. Then your company deploys its own AI platform and something feels off. It hedges. It refuses. It does not understand your business, markets, or data. You are not imagining...
Blog
From Patent Cliff to AI Gaps: Six Commercialization Challenges Shaping Pharma in 2026
Trinity recently convened its leadership team to examine the scale of the industry’s current commercialization challenges and stress test the solutions we are bringing to clients. Our senior leadership articulated the six most material issues facing biopharma today and created space...
